The CDC Opioid Prescribing Guidelines for 2022 are currently in draft formulation after development and stakeholder input. The draft guidelines will more than likely be released later this year. Thus far, the draft guidelines have been disseminated for review and comment. This also includes public comment. The new guidelines will focus on being used as a clinical tool to improve communication between clinicians and patients and empower them to make informed, person-center decisions related to pain care together. CDC recognizes that the 2016 Guidelines were often applied as inflexible standards of care by healthcare professionals, health systems, pharmacies, third-party payers or governmental jurisdictions. This presentation will focus on the key points of the CDC Guidelines of 2022. Focus will be on patient selection for opioid therapy, non-opioid therapy treatment options and the appropriate use of opioid therapy. Emphasis will be made on the risks of opioid therapy to include Opioid Use Disorder and other side effects of chronic opioid therapy. High dose opioid prescribing as well as the management of opioid tapers and discontinuation of therapy will be emphasized as this was a significant concern of the CDC after the release of the 2016v Guidelines. Forced tapering and rapid weaning led to significantly worse patient outcomes and subsequent warnings from the FDA and CDC. Learning Objectives: Develop an understanding of the newer guidelines and position statements regarding the use of chronic opioid therapy as well as an emphasis on the balanced management of pain and the risks associated with opioids. Gain knowledge in the risk assessment of chronic pain patients and the appropriate management of these patients in a multi-modal treatment plan. Understand and incorporate safe measures for tapering and weaning opioid medications and the associated risks to include abandonment, poor outcome, drug overdose and suicide. A review of the implications of SB 1446/848 in the management of acute and chronic pain patients and how it impacts your practice. *This program meets the requirements set forth in Oklahoma SB1446/848 for pain management, opioid use or addiction education for MDs and PAs and the Proper Prescribing credit required by the Oklahoma State Board of Osteopathic Examiners.

Child psychiatry access programs (CPAP) offer the opportunity to support the primary care provider in the provision of child and adolescent mental health care. The implementation of this program also attenuates the gap in needed services for children and families managing mental health symptoms. The history of CPAPs and the Pediatric Mental Health Care Access (PMHCA) program will be reviewed. Specific CPAP capacities will be discussed. Oklahoma’s history with CPAP and Oklahoma’s PMHCA award will be reviewed. Oklahoma’s PMHCA is titled Oklahoma Child and Adolescent Psychiatry and Mental Health Access Program (OK CAPMAP). OK CAPMAP will provide Oklahoma's primary care providers with child and adolescent psychiatry and mental health consultation, cutting-edge behavioral health education, and comprehensive referral assistance to local and statewide mental health services. The provision of services offered by OK CAPMAP will be further described, discussed, and demonstrated.

The CDC Opioid Prescribing Guidelines for 2022 are currently in draft formulation after development and stakeholder input. The draft guidelines will more than likely be released later this year. Thus far, the draft guidelines have been disseminated for review and comment. This also includes public comment. The new guidelines will focus on being used as a clinical tool to improve communication between clinicians and patients and empower them to make informed, person-center decisions related to pain care together. CDC recognizes that the 2016 Guidelines were often applied as inflexible standards of care by healthcare professionals, health systems, pharmacies, third-party payers or governmental jurisdictions. This presentation will focus on the key points of the CDC Guidelines of 2022. Focus will be on patient selection for opioid therapy, non-opioid therapy treatment options and the appropriate use of opioid therapy. Emphasis will be made on the risks of opioid therapy to include Opioid Use Disorder and other side effects of chronic opioid therapy. High dose opioid prescribing as well as the management of opioid tapers and discontinuation of therapy will be emphasized as this was a significant concern of the CDC after the release of the 2016v Guidelines. Forced tapering and rapid weaning led to significantly worse patient outcomes and subsequent warnings from the FDA and CDC. Learning Objectives: Develop an understanding of the newer guidelines and position statements regarding the use of chronic opioid therapy as well as an emphasis on the balanced management of pain and the risks associated with opioids. Gain knowledge in the risk assessment of chronic pain patients and the appropriate management of these patients in a multi-modal treatment plan. Understand and incorporate safe measures for tapering and weaning opioid medications and the associated risks to include abandonment, poor outcome, drug overdose and suicide. A review of the implications of SB 1446/848 in the management of acute and chronic pain patients and how it impacts your practice. *This program meets the requirements set forth in Oklahoma SB1446/848 for pain management, opioid use or addiction education for MDs and PAs and the Proper Prescribing credit required by the Oklahoma State Board of Osteopathic Examiners.

In our diverse world, it's easy to become frustrated when navigating through the web of personalities and paradigms that surround us. Whether at work or in your personal life, dealing with differences often tops the list of 'core challenges'. In acknowledging and exploring those differences, you can turn confusion into connections; indifference into insight; and frustration into fascination. Though we can't promise this will change your world, it may very well change how you see the world!

We will review the history of healthcare policy related to combustible nicotine products and the market shift towards vape-based delivery systems and electronic cigarettes. This talk will explore both the public health implication of policy changes as well as the medical literature to understand risk to patients associated with recommendations as they have evolved overtime.

The CDC Opioid Prescribing Guidelines for 2022 are currently in draft formulation after development and stakeholder input. The draft guidelines will more than likely be released later this year. Thus far, the draft guidelines have been disseminated for review and comment. This also includes public comment. The new guidelines will focus on being used as a clinical tool to improve communication between clinicians and patients and empower them to make informed, person-center decisions related to pain care together. CDC recognizes that the 2016 Guidelines were often applied as inflexible standards of care by healthcare professionals, health systems, pharmacies, third-party payers or governmental jurisdictions. This presentation will focus on the key points of the CDC Guidelines of 2022. Focus will be on patient selection for opioid therapy, non-opioid therapy treatment options and the appropriate use of opioid therapy. Emphasis will be made on the risks of opioid therapy to include Opioid Use Disorder and other side effects of chronic opioid therapy. High dose opioid prescribing as well as the management of opioid tapers and discontinuation of therapy will be emphasized as this was a significant concern of the CDC after the release of the 2016v Guidelines. Forced tapering and rapid weaning led to significantly worse patient outcomes and subsequent warnings from the FDA and CDC. Learning Objectives: Develop an understanding of the newer guidelines and position statements regarding the use of chronic opioid therapy as well as an emphasis on the balanced management of pain and the risks associated with opioids. Gain knowledge in the risk assessment of chronic pain patients and the appropriate management of these patients in a multi-modal treatment plan. Understand and incorporate safe measures for tapering and weaning opioid medications and the associated risks to include abandonment, poor outcome, drug overdose and suicide. A review of the implications of SB 1446/848 in the management of acute and chronic pain patients and how it impacts your practice. *This program meets the requirements set forth in Oklahoma SB1446/848 for pain management, opioid use or addiction education for MDs and PAs and the Proper Prescribing credit required by the Oklahoma State Board of Osteopathic Examiners.

In our diverse world, it's easy to become frustrated when navigating through the web of personalities and paradigms that surround us. Whether at work or in your personal life, dealing with differences often tops the list of 'core challenges'. In acknowledging and exploring those differences, you can turn confusion into connections; indifference into insight; and frustration into fascination. Though we can't promise this will change your world, it may very well change how you see the world!